Search Results

Invenra Inc., an innovative leader in bispecific antibody technology, is pleased to announce a strategic collaboration with Catalent, a global Contract Development and Manufacturing Organization (CDMO) specializing in innovative drug development solutions.

Invenra Inc., an innovative leader in bispecific antibody technology, is pleased to announce a strategic research agreement with Astellas Pharma, a global pharmaceutical company with a vision to turn innovative science into value for patients.

Invenra announced that Chief Scientific Officer Daniel Pereira, Ph.D., will present preclinical data supporting the ongoing development of INV322, an antibody-based cancer therapeutic.

Invenra, Inc., a biotechnology company focused on the discovery and development of multispecific antibodies for immuno-oncology, today announced the appointment of Daniel S. Pereira, Ph.D., as Chief Scientific Officer.

Exelixis, Inc. (Nasdaq: EXEL) and Invenra, Inc. today announced that they have expanded their discovery and licensing collaboration to include an additional 20 oncology targets.

Invenra Inc. announced that it has expanded its collaboration with Exelixis, Inc.

Invenra is pleased to announce and welcome back, Mark F. Kubik as Chief Business Officer. Mark will lead the Invenra business development team, developing and managing new business opportunities in addition to leadership of alliance and portfolio management, and overseeing its pipeline of immuno-oncology bispecific (B-Body™) antibodies and strategic partnerships.

Invenra and WARF (Wisconsin Alumni Research Foundation) today announced they have entered into a collaboration to discover and develop a bispecific antibody therapeutic for the treatment of neuroblastoma, a cancer that is the third most common

Exelixis, Inc. announced that it has entered into a collaboration with Invenra, Inc.